Peptide detail

Semaglutide

Semaglutide (Wegovy/Ozempic) has revolutionized weight loss treatment as a highly effective GLP-1 receptor agonist. Its long half-life of approximately one week allows for once-weekly dosing, making it more convenient than earlier GLP-1 medications. Clinical trials have shown average weight loss of 12-15% of body weight at the 2.4mg dose, with significant improvements in quality of life and obesity-related comorbidities. The medication works through multiple pathways: reducing hunger and food cravings, increasing feelings of fullness, slowing gastric emptying, and improving insulin sensitivity. Beyond weight loss, it has demonstrated significant benefits in reducing cardiovascular risk, improving blood pressure, and enhancing metabolic health. The medication has been particularly effective in individuals with obesity-related conditions such as type 2 diabetes, where it provides dual benefits of weight loss and improved glycemic control.